Elena Myasoedova1, Arun Chandran2, Birkan Ilhan3, Brittny T Major4, C John Michet2, Eric L Matteson5, Cynthia S Crowson6. 1. Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA Division of Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. 2. Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. 3. Department of Internal Medicine, Division of Geriatrics, Istanbul University, Istanbul School of Medicine, Istanbul, Turkey. 4. Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA. 5. Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA. 6. Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
Abstract
OBJECTIVE: To examine the role of rheumatoid arthritis (RA) flare, remission and RA severity burden in cardiovascular disease (CVD). METHODS: In a population-based cohort of patients with RA without CVD (age ≥30 years; 1987 American College of Rheumatology criteria met in 1988-2007), we performed medical record review at each clinical visit to estimate flare/remission status. The previously validated RA medical Records-Based Index of Severity (RARBIS) and Claims-Based Index of RA Severity (CIRAS) were applied. Age- and sex-matched non-RA subjects without CVD comprised the comparison cohort. Cox models were used to assess the association of RA activity/severity with CVD, adjusting for age, sex, calendar year of RA, CVD risk factors and antirheumatic medications. RESULTS: Study included 525 patients with RA and 524 non-RA subjects. There was a significant increase in CVD risk in RA per time spent in each acute flare versus remission (HR 1.07 per 6-week flare, 95% CI 1.01 to 1.15). The CVD risk for patients with RA in remission was similar to the non-RA subjects (HR 0.90, 95% CI 0.51 to 1.59). Increased cumulative moving average of daily RARBIS (HR 1.16, 95% CI 1.03 to 1.30) and CIRAS (HR 1.38, 95% CI 1.12 to 1.70) was associated with CVD. CVD risk was higher in patients with RA who spent more time in medium (HR 1.08, 95% CI 0.98 to 1.20) and high CIRAS tertiles (HR 1.18, 95% CI 1.06 to 1.31) versus lower tertile. CONCLUSIONS: Our findings show substantial detrimental role of exposure to RA flare and cumulative burden of RA disease severity in CVD risk in RA, suggesting important cardiovascular benefits associated with tight inflammation control and improved flare management in patients with RA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVE: To examine the role of rheumatoid arthritis (RA) flare, remission and RA severity burden in cardiovascular disease (CVD). METHODS: In a population-based cohort of patients with RA without CVD (age ≥30 years; 1987 American College of Rheumatology criteria met in 1988-2007), we performed medical record review at each clinical visit to estimate flare/remission status. The previously validated RA medical Records-Based Index of Severity (RARBIS) and Claims-Based Index of RA Severity (CIRAS) were applied. Age- and sex-matched non-RA subjects without CVD comprised the comparison cohort. Cox models were used to assess the association of RA activity/severity with CVD, adjusting for age, sex, calendar year of RA, CVD risk factors and antirheumatic medications. RESULTS: Study included 525 patients with RA and 524 non-RA subjects. There was a significant increase in CVD risk in RA per time spent in each acute flare versus remission (HR 1.07 per 6-week flare, 95% CI 1.01 to 1.15). The CVD risk for patients with RA in remission was similar to the non-RA subjects (HR 0.90, 95% CI 0.51 to 1.59). Increased cumulative moving average of daily RARBIS (HR 1.16, 95% CI 1.03 to 1.30) and CIRAS (HR 1.38, 95% CI 1.12 to 1.70) was associated with CVD. CVD risk was higher in patients with RA who spent more time in medium (HR 1.08, 95% CI 0.98 to 1.20) and high CIRAS tertiles (HR 1.18, 95% CI 1.06 to 1.31) versus lower tertile. CONCLUSIONS: Our findings show substantial detrimental role of exposure to RA flare and cumulative burden of RA disease severity in CVD risk in RA, suggesting important cardiovascular benefits associated with tight inflammation control and improved flare management in patients with RA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Elke E A Arts; Jaap Fransen; Alfons A den Broeder; Calin D Popa; Piet L C M van Riel Journal: Ann Rheum Dis Date: 2014-01-23 Impact factor: 19.103
Authors: George A Wells; Maarten Boers; Beverley Shea; Peter M Brooks; Lee S Simon; C Vibeke Strand; Daniel Aletaha; Jennifer J Anderson; Claire Bombardier; Maxime Dougados; Paul Emery; David T Felson; Jaap Fransen; Dan E Furst; Johanna M W Hazes; Kent R Johnson; John R Kirwan; Robert B M Landewé; Marissa N D Lassere; Kaleb Michaud; Maria Suarez-Almazor; Alan J Silman; Josef S Smolen; Desiree M F M Van der Heijde; Piet L C M van Riel; Fred Wolfe; Peter S Tugwell Journal: J Rheumatol Date: 2005-10 Impact factor: 4.666
Authors: Gladys Ting; Sebastian Schneeweiss; Jeffrey N Katz; Michael E Weinblatt; Danielle Cabral; Richard E Scranton; Daniel H Solomon Journal: J Rheumatol Date: 2005-09 Impact factor: 4.666
Authors: F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra Journal: Arthritis Rheum Date: 1988-03
Authors: Masayo Sato; Sebastian Schneeweiss; Richard Scranton; Jeffrey N Katz; Michael E Weinblatt; Jerry Avorn; Gladys Ting; Nancy A Shadick; Daniel H Solomon Journal: Arthritis Res Ther Date: 2006-03-14 Impact factor: 5.156
Authors: Gladys Ting; Sebastian Schneeweiss; Richard Scranton; Jeffrey N Katz; Michael E Weinblatt; Melissa Young; Jerry Avorn; Daniel H Solomon Journal: Arthritis Res Ther Date: 2008-08-21 Impact factor: 5.156
Authors: Vital Da Silva Domingues; Ana M Rodrigues; Sara S Dias; Luís Delgado; Ebrahim Barkoudah; Jaime Branco; Helena Canhão Journal: Rheumatol Int Date: 2021-01-03 Impact factor: 2.631
Authors: Susan J Bartlett; Skye P Barbic; Vivian P Bykerk; Ernest H Choy; Rieke Alten; Robin Christensen; Alfons den Broeder; Bruno Fautrel; Daniel E Furst; Francis Guillemin; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; Pamela Montie; Christoph Pohl; Marieke Scholte Voshaar; Thasia G Woodworth; Clifton O Bingham Journal: J Rheumatol Date: 2017-08-15 Impact factor: 4.666
Authors: Katie Bechman; Lieke Tweehuysen; Toby Garrood; David L Scott; Andrew P Cope; James B Galloway; Margaret H Y Ma Journal: J Rheumatol Date: 2018-09-01 Impact factor: 4.666